BACKGROUND We describe the retinal findings in a patient affected by primary membranous nephropathy (MN). CASE REPORT A 61-year-old man presented with a 3-month history of metamorphopsia and decreased visual acuity in both eyes. He was affected by nephrotic syndrome in primary MN and treated with systemic corticosteroids. Dilated fundus examination, optical coherence tomography, and fundus fluorescein angiography revealed the presence of peripapillary choroidal neovascularization (CNV) in the right eye and peripheral CNV in the left eye. A serous retinal detachment with gravitational tract was also observed in both eyes. The patient was treated with intravitreal bevacizumab in the right eye and oral corticosteroids were discontinued. Both eyes achieved a morphological and functional improvement. CONCLUSIONS We present the first case of primary MN associated with CNV, possibly secondary to central serous chorioretinopathy, successfully treated with intravitreal bevacizumab and discontinuation of oral corticosteroids.
Choroidal Neovascularization in Primary Membranous Nephropathy
Gambato T.;Francescutti L.;Lanzetta P.
2020-01-01
Abstract
BACKGROUND We describe the retinal findings in a patient affected by primary membranous nephropathy (MN). CASE REPORT A 61-year-old man presented with a 3-month history of metamorphopsia and decreased visual acuity in both eyes. He was affected by nephrotic syndrome in primary MN and treated with systemic corticosteroids. Dilated fundus examination, optical coherence tomography, and fundus fluorescein angiography revealed the presence of peripapillary choroidal neovascularization (CNV) in the right eye and peripheral CNV in the left eye. A serous retinal detachment with gravitational tract was also observed in both eyes. The patient was treated with intravitreal bevacizumab in the right eye and oral corticosteroids were discontinued. Both eyes achieved a morphological and functional improvement. CONCLUSIONS We present the first case of primary MN associated with CNV, possibly secondary to central serous chorioretinopathy, successfully treated with intravitreal bevacizumab and discontinuation of oral corticosteroids.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.